OncoMatch/Clinical Trials/NCT07796789
Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
Is NCT07796789 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies Nanocrystalline Megestrol Acetate Oral Suspension for nasopharyngeal cancinoma (npc).
Treatment: Nanocrystalline Megestrol Acetate Oral Suspension — This phase III randomized, double-blind, placebo-controlled trial evaluates whether nanocrystalline megestrol acetate can reduce anorexia in patients with locally advanced nasopharyngeal carcinoma (NPC) undergoing concurrent chemoradiotherapy (CCRT). The study aims to confirm the clinical benefits of adding this agent to standard CCRT for improving appetite, quality of life, nutritional status, and survival outcomes.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: antitumor therapy
Exception: induction chemotherapy permitted according to the study protocol
Prior antitumor therapy, including chemotherapy, radiotherapy, or surgery, other than induction chemotherapy permitted according to the study protocol
Cannot have received: radiotherapy to the primary tumor
No prior radiotherapy to the primary tumor
Lab requirements
Blood counts
neutrophil count ≥1.5 × 10⁹/L, hemoglobin ≥90 g/L, platelet count ≥100 × 10⁹/L
Kidney function
serum creatinine ≤1.5 × ULN or calculated creatinine clearance (CrCl) ≥60 mL/min using the Cockcroft-Gault formula
Liver function
ALT and AST ≤2.5 × ULN, total bilirubin ≤2.0 × ULN, serum albumin ≥30 g/L
Adequate organ function, defined as follows: * Hematologic function: neutrophil count ≥1.5 × 10⁹/L, hemoglobin ≥90 g/L, and platelet count ≥100 × 10⁹/L. * Coagulation function: INR, PT, or aPTT ≤1.5 × ULN. * Hepatic function: ALT and AST ≤2.5 × ULN, total bilirubin ≤2.0 × ULN, and serum albumin ≥30 g/L. * Renal function: serum creatinine ≤1.5 × ULN or calculated creatinine clearance (CrCl) ≥60 mL/min using the Cockcroft-Gault formula.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07796789 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage II or III is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages